Top Stories News

Bayer's incoming CEO Marijn Dekkers told reporters that he's prepared to spend up to $23 billion to beef up the company's healthcare business.

Porsolt has opened a new preclinical contract research facility in San Antonio, TX.

More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality the number of missed doses could be...

There are vast, untapped opportunities to start up and develop life science companies across the UK according to a new report, UK Life Science Start-Up Report 2010.

More drugs are hitting the recall list these days. As CNN Money reports, the number of recalls hit 1,742 last year--that's an increase of 309 percent over 2008.

Another fast-track drug is under FDA scrutiny. The Shire blood-pressure drug ProAmantine won agency approval in 1996 under its accelerated approval process. But follow-up studies required by that program--to confirm that it was really as effective as b...

A federal judge has recommended that Watson Pharmaceuticals CEO Paul Bisaro be forced to testify in a Federal Trade Commission probe of a patent settlement between the generic drugmaker and Cephalon over the narcolepsy drug Provigil, Dow Jones reports...

Shire says it is removing its low-blood pressure drug ProAmatine from the market, as it isn't profitable enough to justify the additional clinical tests that the FDA is requiring to stay on the market.

Drug counterfeiting has become a $200-billion business annually, according to the World Customs Organization. By some calculations, the counterfeiting trade has become more lucrative than the narcotics business. It's a global problem. And experts say t...

The cost of a pharmaceutical ingredient is determined by far more than its monetary value. Hilary Ayshford talked to Tom Beil, vice president of quality at SAFC, about the ways in which the industry is seeking to protect itself.

Reaxa ceo, Dr Pete Jackson, illustrates how EnCat technology is proving to be cost-effective in simplifying process work-up for pharma production at scale.